exercise tolerance improves with erythropoietin

Exercise tolerance improves with erythropoietin 11 transfusion-dependent patients with chronic renal failure who required regular haemodialysis received IV erythropoietin (EPO) 100 U/kg 3 times weekly increased by 50 U/kg every 3 weeks to a maximum of 200 U/kg or until haemoglobin levels increased by 5% of the level at the beginning of the trial. Maintenance levels were then individually adjusted. All 11 patients became independent of blood transfusions and 6 patients achieved haemoglobin levels of 100 gil. Four patients failed to reach target haemoglobin levels, these patients had significantly higher serum aluminium concentrations than fully responding patients. Combined therapy with EPO and deferoxamine [desferrioxamine] in these patients resulted in target haemoglobin levels within 4 weeks. EPO dose was reduced steadily in these 4 patients and 2 patients were eventually maintained on deferoxamine only. Thrombocyte counts increased within 2 weeks of the initiation of therapy and remained stable, below normal limits, for 30 weeks of treatment. Ferritin levels significantly decreased in all but 1 patient within 4 weeks of the onset of EPO therapy, and fell steadily throughout the treatment period . Aerobic capacity and oxygen uptake were significantly improved with EPO therapy and maximum HR decreased. Lean body mass increased and fat mass decreased, but body weights remained constant. Reported adverse effects Included rash and fever in 1 patient, which recurred with every EPO dose and also when the vehicle only was tested, transient cerebral ischaemic attack in a patient with general arteriosclerosis and hypertensive encephalopathy in 1 patient. Patients with hypertension prior to the study required intensified therapy and 1 patient developed hypertension which was controlled by therapy. Rosenlal K. GronhagerHlska c. SOVllarVI A. Honkanen E, r,kkanen I, el al BenefiCial e lfecls of erylhropOlelin on haem31010glcal paramelers. aerobiC capaclly. and body flUId composilion In pallen Is In liaE' lIl Ul hal ysls Journal 01ln lern31 MediCine 226 311 ·317, Nov 1989 "" 1 0 INPHARMA - 18 Nov 1989 0156-2703/89/1118-0010/0S01,00/ 0 © ADIS Press

Upload: vuongkhuong

Post on 18-Mar-2017

219 views

Category:

Documents

0 download

Report

Download

Embed Size (px):

TRANSCRIPT

Exercise tolerance improves with erythropoietin

11 transfusion-dependent patients with chronic renal failure who required regular haemodialysis received IV erythropoietin (EPO) 100 U/kg 3 times weekly increased by 50 U/kg every 3 weeks to a maximum of 200 U/kg or until haemoglobin levels increased by ~ 5% of the level at the beginning of the trial. Maintenance levels were then individually adjusted.

All 11 patients became independent of blood transfusions and 6 patients achieved haemoglobin levels of ~ 100 gil. Four patients failed to reach target haemoglobin levels, these patients had significantly higher serum aluminium concentrations than fully responding patients . Combined therapy with EPO and deferoxamine [desferrioxamine] in these patients resulted in target haemoglobin levels within 4 weeks. EPO dose was reduced steadily in these 4 patients and 2 patients were eventually maintained on deferoxamine only. Thrombocyte counts increased within 2 weeks of the initiation of therapy and remained stable, below normal limits, for 30 weeks of treatment. Ferritin levels significantly decreased in all but 1 patient within 4 weeks of the onset of EPO therapy, and fell steadily throughout the treatment period.

Aerobic capacity and oxygen uptake were significantly improved with EPO therapy and maximum HR decreased. Lean body mass increased and fat mass decreased, but body weights remained constant.

Reported adverse effects Included rash and fever in 1 patient, which recurred with every EPO dose and also when the vehicle only was tested, transient cerebral ischaemic attack in a patient with general arteriosclerosis and hypertensive encephalopathy in 1 patient. Patients with hypertension prior to the study required intensified therapy and 1 patient developed hypertension which was controlled by therapy. Rosenlal K. GronhagerHlska c. SOVllarVI A. Honkanen E, r,kkanen I,

el al BenefiCial elfecls of erylhropOlelin on haem31010glcal paramelers. aerobiC capaclly . and body flUId composilion In pallen Is In liaE'lIlUlhalysls Journal 01ln lern31 MediCine 226 311 ·317, Nov 1989 ""

1 0 INPHARMA - 18 Nov 1989 0156-2703/89/1118-0010/0S01 ,00/ 0 © ADIS Press

Erythropoietin - Cold Spring Harbor Perspectives in …perspectivesinmedicine.cshlp.org/content/3/3/a011619.full.pdf · Erythropoietin H. Franklin Bunn Hematology Division, Department

Alternatives to RBC Transfusion: Erythropoietin and beyond Shimabukuru... · Alternatives to RBC Transfusion: Erythropoietin and beyond ... independence) Corwin, ... Characteristic

Evolved Cobalamin-Independent Methionine Synthase (MetE ...Evolved Cobalamin-Independent Methionine Synthase (MetE) Improves the Acetate and Thermal Tolerance of Escherichia coli

A Semi-Dominant Mutation in OsCESA9 Improves Salt ......ORIGINAL ARTICLE Open Access A Semi-Dominant Mutation in OsCESA9 Improves Salt Tolerance and Favors Field Straw Decay Traits

Distinct roles of erythropoietin, insulin-like growth

Erythropoietin administration partially prevents adipose tissue loss

Development of tracking and timing sensors and imagers at FBK...Radiation tolerance. Acceptor . Smaller c, Removal. improved tolerance. Addition of carbon improves by a factor ~2 the

The Association between erythropoietin, vitamin D3 and

Polycythemia in transgenic miceexpressingthe human ... · polycythemia dueto increased erythropoietin levels. Theglycoprotein hormone erythropoietin (EPO) is the pri-mary humoral

Construction ofan EPO (Human-Erythropoietin) Synthetic

Human Erythropoietin - resources.rndsystems.com · Human Erythropoietin Immunoassay Quantikine ... sleep apnea, high-affinity hemoglobinopathy, smoking, or localized renal hypoxia